EMA Considering Guideline On Evaluating Novel Antivirals for Influenza
Executive Summary
The European Medicines Agency has identified a host of problems companies face in developing novel antiviral agents for treating influenza. It aims to clarify EU regulatory expectations on these issues through a new guideline that could be ready for consultation in Q1 2018.